Rearrangement of the mixed lineage leukaemia (MLL) gene with extra eleven nineteen (EEN) was previously identified in an infant with acute myeloid leukaemia. Using homologous recombination, we have created a mouse equivalent of the human MLL-EEN allele and showed that when Mll Een/ þ embryonic stem (ES) cells were induced to differentiate in vitro into haemopoietic cells, there was increased proliferation of myeloid progenitors with self-renewal property. We also generated Mll
Introduction
The mixed lineage leukaemia (MLL) gene (also referred to as HRX, ALL-1 and Htrx) located on human chromosome 11q23 is a major regulator of Hox homeobox genes, which are required for normal embryonic development and establishment of haemopoiesis. [1] [2] [3] [4] The MLL gene is frequently rearranged as a result of chromosomal translocations in leukaemias to create chimeric genes consisting of 5 0 MLL sequences fused in-frame to 3 0 partner gene sequences. MLL fusion genes are present in 5-10% of childhood and adult leukaemias as well as in the majority of infant leukaemias and secondary leukaemias arising in patients treated with topoisomerase II inhibitors. [5] [6] [7] [8] On the whole, leukemic patients with MLL fusion genes have a poor prognosis on conventional chemotherapeutic regimens with the worst outcome seen in the infant group. 9, 10 The pathogenic properties of MLL fusion genes have been confirmed both from in vitro cellular transformation studies as well as in vivo mouse models of leukaemias developed from either the homologous recombination approach in embryonic stem (ES) cells or via retrovirus transduction/transplantation (RTT) of enriched haemopoietic progenitor cells (reviewed by Ayton and Cleary, 11 Daser and Rabbitts 12 ). To date, nine mouse models of MLL fusion genes (i.e. ENL, CBP, ELL, AF10, AFX, FKHRL1, AF1p, GAS7 and SEPT6) [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] have been generated through the RTT approach compared to four (i.e. AF9, ENL, CBP and AF4) [23] [24] [25] [26] [27] [28] achieved through the gene targeting approach. Consistent with gene profiling studies from patients with MLL translocations, [29] [30] [31] mouse models have confirmed deregulation of Hox genes mediated either through transactivation of the MLL fusion protein or dimerization of MLL contributed by the fusion partner to be a critical step for leukemic transformation. However, the requirement for specific subsets of Hox genes in leukemic transformation in mouse models mediated by MLL fusion genes appears to vary depending on the type of fusion partner and on the approach used for generating the mutant mice. [32] [33] [34] [35] Besides MLL-AF9 36 and MLL-CBP 26 mouse models, there have been no other studies performed to study the early effects of MLL fusion protein on haemopoietic development and its impact on Hox expression in pre-leukemic phase. These studies are pertinent given the multistep pathogenesis of human leukaemias and the in utero origin of some MLL fusion proteins.
The MLL-EEN gene was first identified in an infant with acute myeloid leukaemia. 37 We have shown that EEN, a member of the endophilin family involved in clathrin-mediated endocytosis, [38] [39] [40] [41] is localized in different subcellular compartments, 42 and as an adaptor protein can act as tumour suppressor in rat fibroblast Ras transformation assays. 43 In vitro studies on the oncogenic role of MLL-EEN have shown that when HL-60 cells are transfected with the fusion gene, the cells show increased proliferation and are more resistant to cell death induced by serum deprivation. 44 In order to study the biological role of MLL-EEN fusion gene in relation to the multistep pathogenesis of leukaemia in a physiological relevant setting, we created Mll Een/ þ mouse ES cells and observed its effect on in vitro haemopoiesis and the pathogenesis of leukaemia in Mll Een/ þ chimeric mice. Our results showed that Mll Een/ þ ES cells led to enhanced proliferation of myeloid progenitors derived from embryoid bodies. The chimeric mice we generated developed leukaemia characterized by organomegaly and infiltration with immature myeloid cells after a latency of at least 3. 
Materials and methods

Construction of Mll-Een targeting vector
The Mll genomic fragment containing exons 8 and 9 of Mll (Probe A, Figure 1a ) was used as a probe to screen a 129Sv/Ev mouse lambda phage genomic library (kind gift of J Rossant). Positive Mll genomic clones containing the translocation breakpoint region from the BamHI site of exons 3-10 were purified and subcloned into the pBluescript KSII þ vector (Stratagene, La Jolla, CA, USA). The Een complementary DNA (cDNA) plasmid (SH3p8) (kind gift of BK Kay) 45 was amplified from exons 2 to 10 of Een and subcloned into the IRES-EGFPloxP-Neo vector. The IRES-EGFP-loxP-Neo vector was derived from the IRES-EGFP plasmid (BD Biosciences, Pharmingen, San Diego, CA, USA) and the pGK loxP Neo plasmid (kind gift of JD Huang). The resulting Een-IRES-EGFP-loxP-Neo DNA fragment was inserted after exon 8 of Mll by bacterial recombination 46 to generate the Mll-Een knockin targeting vector (Figure 1b) . The inclusion of IRES-EGFP facilitates detection of cells that expressed the Mll-Een fusion protein. Integrity of the DNA sequences of the various vectors was confirmed after each cloning step.
Generation of Mll
Een/ þ ES cells and chimeric mice
The Mll-Een knockin targeting vector was introduced into L4 ES cells established from 129 Sv/Ev blastocysts in our Transgenic Core Facility (R Lung and KSE Cheah, unpublished) and ES cell clones carrying the desired targeted Mll Een/ þ allele were identified by Southern blot analysis. Chimeric mice were generated by injecting Mll Een/ þ ES cells into C57BL/6 blastocysts. The Mll lacZ/ þ -targeted ES cells are E14 (129/Ola) cells with fusion of lacZ into exon 8 of the Mll locus (kind gift of TH Rabbitts). 47 Both L4 cells and E14 ES cells were from the 129 strain of mouse.
Haemopoietic differentiation of Mll
Een/ þ ES cells
The schedule for in vitro differentiation of ES cells to the haemopoietic lineage is summarized in Figure 2a . ES cells were maintained as stem cells on mitomycin C inactivated feeder layer. At 48 h before differentiation, the ES cells were adapted to Iscove's modified Dulbecco's medium (IMDM), and on day 0, ES cells (5 Â 10 3 ) were added to 1 ml of IMDM medium containing stem cell factor (SCF) and 1% methylcellulose as described in the supplier's instructions (Stem Cell Technologies, Vancouver, BC, Canada). Embryoid bodies (EBs) were formed in culture by plating on bacteriological dishes. At day 5, 7 and 9, the total number of EBs and cells dissociated from EBs were counted. Colony-forming assays were performed by culturing 5 Â 10 4 cells in 1 ml of IMDM containing 1% methylcellulose, 15% fetal bovine serum (FBS), 2 mM L-glutamine, 150 mM monothioglycerol (MTG), 1% bovine serum albumin, 10 mg/ ml insulin, 200 mg/ml transferin, 100 ng/ml mSCF, 30 ng/ml mouse interleukin-3 (mIL-3), 30 ng/ml IL-6 and 40 ng/ml granulocyte-monocyte-colony-stimulating factor (GM-CSF). At day 7, the numbers of colony-forming units-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM), colonyforming units-granulocyte and macrophages (CFU-GM) and colony-forming units-erythroid (CFU-E) colonies were scored for cell clusters of more than 200 cells. For fluorescence-activated cell sorter (FACS) analysis, the culture was scaled up 10 times by plating 5 Â 10 5 ES cells in 10 ml of culture medium.
Replating assays for self-renewal property Cells (1 Â 10 5 ) from haemopoietic colonies derived from day 7 and 9 EBs were cultured in semisolid methylcellulose medium containing haemopoietic cytokines as described in the previous section. At day 7, the numbers of CFU-GEMM, CFU-GM and CFU-E colonies were counted, and the colonies harvested and plated at a concentration of 1 Â 10 5 cells/ml. Replating was performed at a 7-day-interval to determine self-renewal. A similar replating assay was performed under similar conditions on BM cells from wild-type and Mll
Een/ þ chimeric mice obtained by flushing the mouse femur with IMDM medium with 10% FBS.
Mouse pathology and immunophenotypic analysis Mll
Een/ þ chimeric mice were killed when they showed signs of distress. Following post-mortem examination, tissues were fixed in 10% formalin, embedded in paraffin wax, sectioned and stained with haematoxylin and eosin (H&E) by routine procedures. Cytospins of BM and peripheral blood (PB) films were fixed in methanol:acetone (80:20) and stained with Wright-Giemsa stain (Sigma Aldrich, St Louis, MO, USA) to assess cell morphology under light microscopy.
Immunophenotypic analysis was performed by labelling the cells harvested from colony assays or from BMs and organs of Mll Een/ þ chimeric mice with a combination of fluorochromeconjugated antibodies against c-kit (biotin), Mac-1 (CD11b, PE), Gr-1 (biotin), B220 (Cy5), IgM (PE), CD4 (Cy5) and CD8 (PE) (BD Biosciences, USA). A secondary streptavidin Per-CP substrate was applied to the biotin-labelled antibody. The percentage of Mll-Een-expressing cells was reflected by the percentage of green fluorescence protein (GFP)-expressing cells. The immunophenotypic analysis was performed with FACScan instrument ('Epics-Altra', Beckman Coulter) with analysis of 10 000 cells in each sample.
Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis
Semiquantitative RT-PCR was performed to study the mRNA expression level of Hoxa7, Hoxa9, Hoxa10, Hoxb4 and Meis1. Total RNA was isolated from cells using TRIzol (Life Technologies, Carlsbad, CA, USA) as recommended by the manufacturer. Two micrograms of total RNA were denatured and reverse transcribed using oligo (dT) 15 primers in a 20 ml reaction. Thereafter, 1 ml of cDNA was amplified in a 20 ml PCR reaction mixture in the presence of specific primers (sequences are available upon request) and within the linear range of amplification cycles. Total RNA extracted from day 14.5 embryo was used as positive control and PCR reaction without cDNA template was used as negative control.
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Results
Generation of Mll Een/ þ ES cells
In the patient with MLL-EEN translocation, exon 6 of MLL is fused in-frame with exon 2 of EEN. To recapitulate the fusion breakpoint found in the human patient, the cDNA of Een was fused in-frame with exon 8 of Mll, which is equivalent to exon 6 of MLL (Figure 1a ). The alignment of the breakpoint region of MLL-EEN fusion and the Mll-Een knockin mutant is illustrated in Figure 1b . 5 cells plated in each round of the self-renewal assay. ES, embryonic stem cell, EBs, embryoid bodies; SCF, stem cell factor; IL, interleukin; GM-CSF, granulocyte-monocyte-colony-stimulating factor; CFU, colony-forming unit; CFU-GEMM, CFU-granulocyte, erythroid, macrophage, megakaryocyte; CFU-GM, CFU-granulocyte and macrophages; CFU-E, CFU-erythroid. Error bar of the bar chart indicated the standard derivations between three independent experiments each were duplicated. Error bar of the bar chart for E-H indicated the standard deviations between three independent experiments, each were duplicated. Photos were taken by Nikon Eclipse TS100 microscope with Â 100 magnification, unless specified.
The targeting vector was introduced into ES cells and five out of six hundred clones screened were identified as targeted clones by Southern blot analysis using 5 0 and 3 0 external probes (Figure 1c) . The targeted ES cells contain the designed gain-offunction Mll-Een fusion gene that mimics the corresponding gene rearrangement found in human leukaemia and the IRES-EGFP that facilitates detection of cells, which express the MllEen fusion protein. As the targeted Mll locus is disrupted by the Een cDNA, the Mll-Een-targeted allele (designated Mll Een ) also carries a concurrent heterozygous loss-of-function mutation of Mll.
Mll
Een/ þ ES cells leads to enhanced proliferation of myeloid progenitors
To investigate the effect of Mll-Een fusion protein on early haemopoietic 47 representing heterozygous loss-of-function mutation of Mll. In the absence of LIF, all three ES cell lines gave rise to EBs as spherical masses of cells surrounded by cellular envelopes with no significant difference in their morphology and growth during the first three days of culture (Figure 2b) . From day 5 onwards, however, there was an approximately two-fold increase in the number of EBs generated from Mll Een/ þ ES cells and EBs expressed GFP throughout the culture (data not shown), this suggests that one of the early effects of the Mll-Een fusion protein on ES cell development is to facilitate the commitment of a higher number of ES cells to form EBs.
We next investigated the haemopoietic colony forming potential of EBs generated from Mll Een/ þ , Mll þ / þ and Mll lacZ/ þ ES cells. Cell suspensions from day 5, day 7 to day 9 EBs were assayed for their potential to differentiate into CFU-GEMM, CFU-GM and CFU-E. In contrast to EBs from Mll þ / þ and Mll lacZ/ þ ES, which gave rise to very small numbers of CFU-GEMM, CFU-GM and CFU-E colonies, day 7 and day 9 EBs, from Mll Een/ þ ES cells produced greater numbers of and larger size colonies (Figure 2c and f) . Immunophenotypic analysis of pooled colonies (day 16) generated from day 9 from Mll Een/ þ EBs showed that more than 70% of the cells were Mac-1 þ immature myeloid cells (Figure 3a) . These results suggest that cells from Mll Een/ þ EBs can differentiate into myeloid lineage with enhanced proliferative capacity.
Myeloid progenitors generated from Mll
Een/ þ EBs have self-renewal property and specific Hox gene profile
We next assessed the proliferative capacity of
and Mll lacZ/ þ myeloid colonies for self-renewal by performing replating assays at 7-day intervals and, at simultaneous time points, RT-PCR analysis of Hoxa7, a9, a10, b4 and Meis1. From the first replating (day 23), Mll Een/ þ myeloid colonies continued to increase in size and number, maintained a high proportion of CFU-GEMM up to the fourth replating (Figure 2d and g ) and expressed GFP (Figure 3c ). Immunophenotypic analysis showed that cells from Mll Een/ þ myeloid colonies before replating (day 16) had a more immature myeloid phenotype with twothreefold increase of c-kit þ /Mac-1 þ (Figure 3a) 
Mll
Een/ þ chimeric mice develop myeloid leukaemia
We investigated the ability of Mll-Een fusion protein in contribution to leukaemogenesis from 15 chimeric mice generated from two independent Mll Een/ þ ES cell clones (clone 1F and clone 4H). We observed no germline transmission of the Mll Een/ þ mutant allele upon examination of 250 offspring obtained from breeding the chimeric mice with wild-type C57BL/6. This suggests that either the knockin Mll Een/ þ mutant allele is embryonic lethal or that the targeted ES cell clones did not contribute to the germline in any of the chimeric mice.
Of these 15 chimeric mice, nine mice (3.5-11 months) were found dead with two in poor conditions; and six were killed when they showed signs of distress. Of 13 mice suitable for tissue examination, there were signs of leukaemia in 11 mice (seven male and four female, the youngest being 3.5 months) as evident by pathologically enlarged thymuses, livers, spleens and lymph nodes, presence of blasts in peripheral blood and Table 1 ). Immunophenotypic analysis of cells from BMs and pathologically enlarged organs by flow cytometry revealed high levels of EGFP expression, which marked Mll-Eenexpressing cells and confirmed the leukemic origin of these cells contributing to organomegaly (Table 1) . We also observed infiltration of leukemic blasts in varying degrees in other nonhaemopoietic organs, that is, interstitium of the kidney, epicardium and interstitium of the myocardium, interstitium between seminiferous tubules and muscle coat of vas deferens were also observed (data not shown). Of the three chimeric mice with no pathological evidence of leukaemia, two appeared normal (e.g. cases 4 and 9; Table 1), with case 4 having low levels of Mll-Een-expressing cells (2% EGFP-positive cells) in the BM; case 9 was not amenable to analysis.
We next performed cell marker studies of myeloid, B-and T-cell lineages on cells from pathologically enlarged organs that were infiltrated by leukemic cells expressing Mll-Een in two mice (cases 6 and 5 with 84% and 50% Mll-Een-expressing cells, respectively). As shown in Figure 4d , the predominant phenotype seen in the total cells as well as the gated population, that is, cells expressing Mll-Een in case 6 was an increase in Mac-1 þ /Gr-1 À (immature myeloid) populations in spleen, thymus, mesenteric lymph node and BM compared to wild type. We also observed increase in blasts in peripheral blood and BM (Figure 4b ) as well as absence of normal B220 þ /IgM þ mature B-cell population in the spleen and mesenteric lymph node, absence of normal CD4 þ /CD8 þ double-positive T cells in the thymus, absence of CD4 and decrease of CD8 single positive T cells in mesenteric lymph node (Figure 4e , second row). In the other less severely affected mouse (i.e. case 5), there were also decrease in normal B-and T-cell populations in spleen and thymus but to a lesser extent (Figure 4e, third row) .
Taken together, the pathological and immunophenotypic findings showed evidence of leukaemia in the chimeric mice and demonstrated a pathogenic role of Mll-Een in the development of myeloid leukaemia.
Mll-Een increases the self-renewal of BM myeloid progenitors
We next investigated whether mouse BM cells expressing Mll-Een have self-renewal property by performing replating assays in the presence of haemopoietic cytokines as described previously. Mll-Een enhanced proliferation and self-renewal of myeloid progenitors up to the fourth replating compared to the wild-type BM cells, which exhausted their proliferation capacity on the second replating (Figure 5a ).
Immunophenotyping analysis of day 7 colonies expressing Mll-Een showed higher levels of c-kit positivity with fewer Mac-1 þ /Gr-1 þ cells compared to the wild-type, which suggests that these cells were at a more immature state (Figure 5b ). EGFP-positive Mll-Een colonies appeared as very compact colonies and contained cells resembling immature myeloid cells by Wright-Giemsa staining (Figure 5c ). These results show that Mll-Een myeloid cells can undergo selfrenewal with impairment of terminal differentiation resembling features typically seen in acute leukaemia.
Hox expression profiles are different between Mll-Een myeloid population derived from ES cells and in the leukemic mice
As Hox genes are believed to be major mediators for MLLmediated leukemogenesis, we assessed the effect of Mll fusion on Hox gene expression in the early developmental stage (e.g. myeloid progenitors derived from Mll-Een ES cells) and in fullblown leukaemia (e.g. Mll Een/ þ leukemic cells) by semiquantitative RT-PCR. Interestingly, we observed that although myeloid progenitors derived from Mll Een/ þ ES cells expressed Hoxa7, a9, b4 and Meis1 before replating, Hoxa7 and a9 were downregulated and only the expression of Meis1 and Hoxb4 were maintained in the subsequent replating (Figure 5d ). Conversely when we examined the expression of Hox genes in the myeloid leukemic cells from chimeric animals, Hoxb4 which was upregulated in Mll
Een/ þ ES cell-derived myeloid progenitors, was not expressed in the leukemic cells. Instead, we observed upregulation of Hoxa7, a9, a10 and Meis1 in cells harvested from the leukemic mouse (with 80% Mll Een/ þ -expressing cells) but not in the non-leukaemia chimeric mouse (with 2% Mll Een/ þ -expressing cells) (Figure 5e ). These results indicate that Mll-Een may differentially regulate the expression of Hox genes during leukemic development.
Discussion
The multistep model of leukaemia development in which genetic mutations accumulate over time leading to the development of clinical disease is supported by the findings in clinical 
The post-mortem characteristics and the level of Mll-Een expression in different organs of the chimeric mice are shown. Percentage of chimerism was determined by the coat colour. M, male; F, female; BM, bone marrow; PB, peripheral blood; LN, mesenteric lymph node; F, not examined. *Blast infiltration as examined by histological sections.
samples as well as from the long latency required to develop overt malignancy in mouse models of human leukaemias. Although there are several mouse models of MLL fusion leukaemias to date, the early effects of the MLL fusion protein on haemopoieitic development have only been examined in the MLL-AF9 and MLL-CBP mice. 36, 26 In both studies, the fusion protein was shown to induce expansion of myeloid progenitors and enhanced self-renewal with the requirement of secondary events for the development of fully established leukaemia. In order to define the role of MLL fusion protein in the pathogenesis of leukaemia in a multistep model, we have used mouse ES cells as the biological platform not only to examine the effects of Mll-Een on the in vitro haemopoietic development of ES cells but also on the pathogenesis of leukaemia development. This was achieved by creating a mouse equivalent of the human MLL-EEN allele by targeted insertion of Een cDNA into the
Mll locus of ES cells via homologous recombination and subsequently generated Mll
Een/ þ chimeric mice. We showed that primary Mll Een/ þ ES cells were enhanced to form Ebs, which can generate myeloid progenitors with enhance proliferation in a replating assay in the presence of haemopoietic cytokines. This is in contrast to Mll þ / þ and Mll lacZ/ þ myeloid progenitors, which proliferate but mature and loose their proliferative capacity after the second replating. The finding that Mll Een/ þ ES myeloid progenitors could be replated up to four times is indicative of self-renewal property, which is necessary but not sufficient on its own for the development of acute leukaemia without further cellular perturbations such as maturation arrest and apoptotic resistance. These self-renewing myeloid progenitors as expected were also shown to have a more immature myeloid phenotype compared to Mll þ / þ and Mll lacZ/ þ myeloid progenitors. Een/ þ chimeras with high (80%) and low (2%) percentage of EGFP expression, respectively. RNA integrity was examined and the amount was normalized to GAPDH. Reaction with RNA from E14.5 whole-mouse embryo or without cDNA template was used as positive and negative control, respectively.
When the Mll
Een/ þ ES cells were put back to blastocyst, we have been successful in generating 15 Mll Een/ þ chimeric mice. No germline transmitted heterozygous mice were created, suggesting that no targeted ES cells could contribute to the germline, or early or high level of expression of Mll-Een is incompatible with life. The 15 Mll Een/ þ chimeric mice have relatively low levels of chimerism based on coat colour. Among 13 chimeric mice analysed, there was evidence of leukaemia in 11 mice based on histopathological examination and immunophenotypic studies, which showed infiltration with immature myeloid cells in BM and in enlarged organs such as the liver, spleen, thymus and lymph node. Interestingly, although signs of leukaemia were observed in both male and female chimeras, most of the chimeras that died suddenly were female (six out of seven). It is coincidental that the only human leukaemia case of MLL-EEN fusion we reported 37 was an affected female. Apart from its functional role in abnormal haemopoiesis, it is not clear whether Mll-Een has other sexually biased functions, which might aggravate the disease conditions.
We also demonstrated that BM progenitor cells expressing Mll-Een could undergo self-renewal in a replating assay. These results provide strong evidence for a pathogenic role of MLL-EEN for the development of myeloid leukaemia, although the long mean latency of 7 months suggests additional secondary events may be necessary for the induction of leukaemia. While part of the oncogenicity of MLL-EEN can be attributed by homodimerization via the coiled-coil domain of EEN, the substantially shorter disease latency of Mll-Een mice compared with those of Mll-lacZ, 47 suggested that Mll-Een is a more potent oncoprotein than just an MLL-dimer. This is also in keeping with our findings that only Mll Een/ þ but not Mll lacZ/ þ ES cells were able to maintain in vitro proliferation of myeloid progenitors.
Previous studies showed that transduction of murine progenitor cells with various MLL fusion genes led to the expression of Hoxa1, a3, a5, a7, a9, a10, a11 and Meis1 genes. 20, 32 However there is evidence from other studies which shows that a single Hox gene such as Hoxa9 under particular experimental settings is absolutely required for MLL-ENL-mediated transformation 32 but not so in MLL-GAS7 or MLL-AF9 mediated transformation. [33] [34] [35] Thus the pathogenic significance of these genes either as whole profiles, subsets or combinations in the development of leukaemia remains to be further clarified. We have previously shown that MLL-EEN can transactivate HoxA7 promoter in HL-60 cells transfected with the fusion gene 44 and our results on Hox gene expression in the Mll Een/ þ chimeric mice is in agreement with previous RTT mouse models, which show upregulation of Hoxa7, a9, a10 and Meis1. 32, 34, 35 However, neither of these critical Hoxa genes were expressed in the active proliferating Mac-1 þ cells derived from Mll Een/ þ ES cells. Instead, we detected overexpression of Hoxb4, another Hox gene that functions to promote self-renewal. This result is reminiscent of recent findings that in hES cell-derived HSCs, 48 the expression patterns of HoxA and HoxB genes are differentially regulated when compared with in vivo HSCs. Moreover, it has been demonstrated that both Hoxa9 and Hoxb4 have the ability to expand HSCs, but overexpression of Hoxb4 will result in enhanced self-renewal without induction of leukaemia. 49, 50 Therefore, Hoxb4 might have distinctive roles in the control of self-renewal of the Mll Een/ þ ES cells. Although we cannot exclude the possibility that the observed Hox expression profiles may simply reflect the developmental status of the cells, these findings also suggest that different waves of Hox expression may be activated by MLL fusion proteins for initiation (in ES cells) and maintenance (in leukaemic cells) of the disease. The consecutive replating ability of Mll-Een-transformed myeloid progenitors derived directly from ES cells in the absence of both Hoxa7 and Hoxa9 strongly indicate the functional redundancy of Hox genes in MLL-mediated leukaemia. Consistent with the previous observation on MLL-GAS7 and MLL-AF9, our results provide further evidence that MLL fusion proteins are unlikely to be absolutely dependent on a single Hox gene for transformation. It will thus be crucial to determine the functional interplay among different Hox genes in MLL-mediated leukaemia.
In conclusion, we have shown that the Mll-Een fusion gene leads to enhanced proliferation of myeloid progenitors derived from mouse ES cells and the development of myeloid leukaemia in chimeric mice. The advantage of the ES cell system is that it can be used to compare the biologic effects of diverse MLL fusion proteins on in vitro haemopoietic development. To provide further insight into the molecular pathogenesis of leukaemia mediated by MLL-EEN, it will be important to generate conditional mouse mutants so that different haemopoietic developmental stages or lineages can be studied. It will also be pertinent to examine other biological mechanisms through which EEN contributes to leukemogenesis as a fusion partner to MLL in future mouse models of the disease. EEN is unique among the fusion partners of MLL, which can dimerize but potentially can function as a tumour suppressor 43 and also in endocytosis which is of particular interest in view of mounting evidence linking deregulation of endocytosis leading to aberrant intracellular signalling and cancer. 51, 52 
